BriaCell Extends Personalized Breast Cancer Immunotherapy To Prostate & Lung Cancer And Melanoma - BriaCe

BriaCell Therapeutics Corp (NASDAQ:BCTX) has advanced its targeted oncology therapeutics into several novel immunotherapy cell lines, including - Bria-Pros for prostate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer.
The company anticipates commencing clinical trials for these novel therapies in 2022.
Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer, remains on track to commence patient dosing in 2021.
Price Action: BCTX shares are up 11.1% at $6.70 during the premarket session on the last check Wednesday.

To add Benzinga News as your preferred source on Google, click here.